GLUE Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 77% planned / 23% discretionary
Largest single sale: $642.7K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Warmuth Markus | President & CEO | Sell | 9,500 | $23.18 | $220.2K | 585,038 −1.6% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 4,351 | $23.38 | $101.7K | 62,371 −6.5% of holding | |
| Townson Sharon 2 fills | Chief Scientific Officer | Sell 10b5-1 | 6,000 | $23.31 | $139.8K | 68,245 −8.1% of holding | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 5,407 | $24.50 | $132.5K | 60,612 −8.2% of holding | |
| Manning Anthony M. | Director | Sell | 10,000 | $23.11 | $231.1K | None left | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 6,000 | $22.95 | $137.7K | 59,992 −9.1% of holding | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 30,000 | $21.42 | $642.7K | 59,992 −33.3% of holding | |
| Janku Filip | Chief Medical Officer | Sell 10b5-1 | 11,845 | $20.22 | $239.5K | 59,992 −16.5% of holding | |
| Townson Sharon | Chief Scientific Officer | Sell 10b5-1 | 3,000 | $20.00 | $60.0K | 67,845 −4.2% of holding | |
| Champoux Jennifer | Chief Operating Officer | Sell 10b5-1 | 2,175 | $20.00 | $43.5K | 62,371 −3.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.